Little is known about the physiological roles of the M5 muscarinic receptor, the last member of the muscarinic receptor family (M1-M5) to be cloned. In the brain, the M5 receptor subtype is preferentially expressed by dopaminergic neurons of the substantia nigra and the ventral tegmental area. Dopaminergic neurons located in the ventral tegmental area are known to play important roles in mediating both the rewarding effects of opiates and other drugs of abuse and the manifestations of opiate͞drug withdrawal symptoms. We therefore speculated that acetylcholine-dependent activation of M 5 receptors might modulate the manifestations of opiate reward and withdrawal. This hypothesis was tested in a series of behavioral, biochemical, and neurochemical studies using M 5 receptor-deficient mice (M5 ؊/؊ mice) as novel experimental tools. We found that the rewarding effects of morphine, as measured in the conditioned place preference paradigm, were substantially reduced in M 5 ؊/؊ mice. Furthermore, both the somatic and affective components of naloxone-induced morphine withdrawal symptoms were significantly attenuated in M 5 ؊/؊ mice. In contrast, the analgesic efficacy of morphine and the development of tolerance to the analgesic effects of morphine remained unaltered by the lack of M 5 receptors. The finding that M 5 receptor activity modulates both morphine reward and withdrawal processes suggests that M 5 receptors may represent a novel target for the treatment of opiate addiction.
T
he M 5 muscarinic receptor is the most recent member of the muscarinic acetylcholine receptor family (M 1 -M 5 ) to be cloned (1, 2) . Owing to the lack of ligands that can selectively stimulate or inhibit the M 5 receptor (3, 4) , the physiological roles of this receptor subtype have remained obscure (5, 6) . To address this issue, we recently used a gene-targeting approach to generate M 5 receptor-deficient mice (M 5 Ϫ/Ϫ mice, ref. 7) . Immunoprecipitation studies have shown that M 5 receptors are expressed at very low levels in the brain, representing less than 2% of the total muscarinic receptor population (M 1 -M 5 ) (8) . Interestingly, M 5 receptor mRNA has been identified as the only muscarinic receptor mRNA in dopamine-containing neurons of the substantia nigra and the ventral tegmental area (VTA) (9, 10) . It has therefore been proposed that M 5 receptors may play a role in modulating dopamine release from midbrain dopaminergic neurons (9, 10) . Consistent with this hypothesis, we recently demonstrated that muscarinic agonist-induced increases in striatal dopamine release were reduced in M 5 Ϫ/Ϫ mice (7). Moreover, Forster et al. (11) recently reported that the sustained increase in dopamine levels in the nucleus accumbens (Acb) observed after electrical stimulation of the laterodorsal tegmental nucleus (12) is absent in M 5 Ϫ/Ϫ mice. Laterodorsal tegmental nucleus neurons represent the major source of cholinergic input to the dopamine-containing neurons of the VTA (13, 14) that project to the Acb and other limbic areas (15) (16) (17) . It is therefore likely that activation of M 5 receptors expressed by VTA neurons (9, 10) is responsible for the prolonged efflux of dopamine in the mouse Acb following laterodorsal tegmental nucleus stimulation (11) .
It is well known that opiates modulate the activity of dopaminergic neurons in the VTA and that this modulation plays an important role in mediating both the rewarding effects of opiates and the opiate withdrawal syndrome (15) (16) (17) . Moreover, previous studies have shown that activation of muscarinic receptors stimulates the activity of dopaminergic VTA neurons (18) (19) (20) (21) . Given the known facilitatory effects of M 5 receptor activation on dopamine release from midbrain dopaminergic neurons (7, 11) , we hypothesized that M 5 receptor activation might modulate the behavioral and neurochemical correlates of drug reward and withdrawal. To test this hypothesis, we initially examined whether inactivation of the M 5 receptor gene affected the rewarding properties of morphine, the prototypical opiate analgesic, and the severity of morphine withdrawal symptoms.
Our data indicate that the rewarding effects of morphine were substantially reduced in M 5 Ϫ/Ϫ mice. Moreover, both the somatic and affective components of the morphine withdrawal syndrome were attenuated in M 5 Ϫ/Ϫ mice. In contrast, the analgesic efficacy of morphine was not affected by the lack of M 5 receptors. We propose that pharmacological blockade of central M 5 receptors may represent an approach for the treatment of opiate (drug) addiction and withdrawal.
Materials and Methods
Animals. The M 5 muscarinic receptor gene was disrupted in mouse TC1 (129SvEv) embryonic stem cells, and M 5 Ϫ/Ϫ mice were generated as described (7) . The M 5 receptor mutation was maintained on a mixed (129SvEv͞CF1, 50%͞50%) or an isogenic (129SvEv) background. M 5 ϩ/ϩ and M 5 Ϫ/Ϫ mice of mixed genetic background (129SvEv͞CF1) were obtained by either homozygous matings (intermating of M 5 ϩ/ϩ or M 5 Ϫ/Ϫ mice, age-matched mice) or heterozygous matings (intermating of M 5 ϩ/Ϫ mice, littermates). Isogenic M 5 ϩ/ϩ and M 5 Ϫ/Ϫ 129SvEv mice were obtained by mating male germ-line chimeras with female 129SvEv mice (Taconic), followed by intermating of F1 offspring heterozygous for the M 5 receptor mutation. The resulting F2 mice were maintained by homozygous matings. All experiments were carried out with male mice that were at least 8 weeks old.
Behavioral Testing. All behavioral tests were performed between 9 a.m. and 5 p.m. The conditioned place preference (CPP)
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apparatus consisted of a rectangular Plexiglas box divided into two compartments (15 ϫ 20 ϫ 18 cm) by a wall with a door. One compartment was black with a wire grid for a floor, and the other one was white with a smooth Plexiglas floor. One week before pretesting, mice were subjected to a 20-min habituation session during which they could freely explore the CPP apparatus. During the pretesting session (20 min, day 1), mice had access to both compartments. The time mice spent in each compartment and the number of transitions between compartments were recorded, and side preference was determined for each animal. On conditioning days 2-9, mice were injected i.p. with either saline or morphine and immediately confined to either the preferred (saline, dark chamber) or the nonpreferred (morphine, white chamber) side, respectively (one 30-min session per day). M 5 ϩ/ϩ and M 5 Ϫ/Ϫ mice were divided into two groups of similar size. One group received saline on days 3, 5, 7, and 9 and morphine on days 2, 4, 6, and 8. The other group received saline on days 2, 4, 6, and 8 and morphine on days 3, 5, 7, and 9. On day 10, side preference was assessed in a 20-min testing session during which mice had free access to both compartments. The time mice spent in each chamber and the number of transitions between the two compartments were recorded. The amount of time mice spent in the nonpreferred compartment of the apparatus during the pretesting (preconditioning) phase was as follows for the M 5 ϩ/ϩ mice: 129SvEv͞CF1, age-matched: 300 Ϯ 33 s, n ϭ 22; 129SvEv͞CF1, littermates: 330 Ϯ 25 s, n ϭ 12; CF1: 200 Ϯ 39 s, n ϭ 12; and 129SvEv: 55 Ϯ 3 s, n ϭ 8. The values obtained with the corresponding M 5 Ϫ/Ϫ mice did not differ significantly from these numbers (data not shown).
For CPP studies assessing the conditioned response to antagonist-precipitated withdrawal, mice were implanted s.c. with a pellet containing morphine (75 mg) or placebo. Habituation and pretesting trials were conducted as described above. Mice were subjected to two conditioning sessions (one 30-min session per day) involving alternating naloxone and saline injections on days 7 and 8 after the implantation of pellets. Naloxone (1 mg͞kg i.p.) was paired with the preferred chamber. Preference testing was carried out 72 h after the last conditioning session.
The times spent in the drug-paired compartment during pretest and testing phases were compared using multiway ANOVA and Bonferroni's post hoc comparison matrix. Place preference conditioning is presented as [(T drug Ϫ T pretest )͞ (T total )] ϫ 100.
The number of occurrences of naloxone (1 mg͞kg i.p.)-induced withdrawal behaviors were recorded over a 30-min period in M 5 ϩ/ϩ and M 5 Ϫ/Ϫ mice implanted with morphine pellets (1 ϫ 75 mg s.c., 7 days). We also examined the effect of concurrent, chronic atropine administration on naloxoneprecipitated morphine withdrawal in M 5 ϩ/ϩ mice implanted with an s.c. morphine pellet (75 mg) and an s.c. osmotic minipump (Alza) delivering atropine sulfate at a rate of 15 mg͞kg per day for 7 days.
Analgesia measurements were performed using the hot-plate and tail-flick tests (22) . Analgesic efficacy is expressed as the percentage of the maximum possible effect ϭ 100 ϫ [(Latency drug Ϫ Latency control )͞(Time cutoff Ϫ Latency control ). The maximum cutoff times for the tail-flick and hot-plate tests were 10 s and 30 s, respectively. Acute tolerance to morphine analgesia was tested by administering a single high dose of morphine (100 mg͞kg i.p.) and determining the analgesic potency of a smaller morphine dose (10 mg͞kg i.p.) 24 h later.
Neurochemistry. For in vivo microdialysis studies, mice were anesthetized with isoflurane, and guide cannulae were implanted above the Acb (ϩ1.7 AP, Ϫ1.0 ML, Ϫ4.2 DV; ref. 23 ). Five days after surgery and 1 day before sampling, a microdialysis probe (CMA 11͞14, 1-mm tip length) was inserted into the guide cannula and perfused with artificial cerebrospinal fluid at a rate of 0.6 l͞min while the mice ambulated on a tether. Samples were collected for 15 min, and dopamine concentrations quantified using HPLC with electrochemical detection (24) . The overall effects of morphine and K ϩ on dialysate dopamine levels were analyzed by calculating area under the curve (AUC) values for each animal and stimulus condition relative to the last basal value. Time course data were analyzed using a two-factor (genotype ϫ time) ANOVA with repeated measures over time and post hoc comparison matrices.
No net flux determination of basal extracellular dopamine concentrations involved perfusion of dopamine (0, 5, 10, 20, and 40 nM) in random order through the dialysis probe (25) . A linear plot of the dialysate dopamine concentrations (DA out ) obtained after perfusion of the various dopamine concentrations (DA in ) was constructed for each animal, (DA in Ϫ DA out ) vs. DA in . The estimated extracellular dopamine concentration is defined as the concentration at which DA in Ϫ DA out ϭ 0.
⌻he density of central -opioid receptors in membrane homogenates from selected brain regions was measured using [ 3 H]DAMGO (5 nM) as a radioligand, essentially as described (26) . D1 and D2 dopamine receptor levels were determined in the presence of 4 nM [ 3 H]SCH23390 and 2 nM [ 3 H]spiperone, respectively, following a published protocol (27) . Data are presented as the mean Ϯ SD of two independent experiments performed in triplicate, with each experiment using tissues pooled from four mice.
M 4 muscarinic receptor levels were assessed using a previously described immunoprecipitation strategy (28) . Membrane preparations were incubated with 2 nM [ 3 H]quinuclidinyl benzilate, a non-subtype selective muscarinic receptor antagonist, and the labeled receptors were solubilized with 1% digitonin. These solubilized, radiolabeled receptors were then immunoprecipitated and quantified with an M 4 receptor-specific antiserum (28) . Data are presented as means Ϯ SD of two independent experiments performed in triplicate, with each experiment using tissues pooled from four mice.
Fos-B expression in the Acb of M 5 ϩ/ϩ and M 5 Ϫ/Ϫ mice was assessed by immunoblot analysis (29) . Acb tissue was removed by frozen micropunch from mice implanted with either placebo or morphine pellets (75 mg͞kg s.c., 7 days) alone or with a combination of pellets and osmotic minipumps delivering atropine sulfate (15 mg͞kg per day s.c., 7 days). Rabbit anti-Fos-B (1:200, Santa Cruz Biotechnology) and rabbit anti-␣-tubulin (1:10,000, Amersham Pharmacia) were used as the primary antibodies. Protein bands were visualized using horseradish peroxidase-conjugated goat anti-rabbit IgG, SuperSignal substrate (Pierce), and film exposure. Data are presented as ratios of calibrated optical densities of Fos-B and ␣-tubulin bands.
Results and Discussion
Morphine-Induced Conditioned Place Preference. As described previously (7), M 5 Ϫ/Ϫ mice (129SvEv͞CF1 hybrids) did not differ significantly from their wild-type littermates in body weight, body temperature, distance traveled in an open field, motor coordination, and several other physiological and behavioral parameters. To examine whether the lack of M 5 receptors was associated with changes in the reinforcing properties of opiates, we used the CPP procedure (22, 30) , a test useful for investigating pathways mediating the rewarding effects of drugs of abuse (30) (31) (32) . In the CPP paradigm, mice learn to associate administration of a drug with one of two compartments which differ visually and texturally (30) .
In M 5 ϩ/ϩ mice, administration of morphine (2.5, 5, 10, and 25 mg͞kg i.p.) significantly increased the amount of time the animals spent in the morphine-associated chamber (Fig. 1A) . In contrast, morphine doses of 2.5, 5, or 10 mg͞kg i.p. failed to induce place preference in M 5 Ϫ/Ϫ mice (Fig. 1 A) . Only the highest morphine dose used (25 mg͞kg i.p.) was effective in producing significant place conditioning in M 5 Ϫ/Ϫ mice ( Fig.  1 A) . However, the magnitude of this effect was significantly smaller than the corresponding response of M 5 ϩ/ϩ mice. The reduction in morphine place preference was observed independent of whether M 5 Ϫ/Ϫ mice (129SvEv͞CF1 hybrids, 50%͞50%) were produced by homozygous matings (agematched mice, Fig. 1 A) or by crosses of heterozygous M 5 ϩ/Ϫ mice (littermates, Fig. 1B ). In addition, the two parental mouse strains (CF1 and 129SvEv) did not differ significantly in the degree of morphine-induced place preference (Fig. 1B) , excluding the possibility that the behavioral deficit displayed by the M 5 Ϫ/Ϫ mice was caused by differences in morphine sensitivity between the CF1 and 129SvEv strains. Consistent with this notion, isogenic M 5 Ϫ/Ϫ mice containing the M 5 receptor mutation on a pure genetic background (129SvEv) also exhibited an attenuated conditioned response to morphine (Fig. 1B) . Together, these observations demonstrate that the reduction in morphine-associated place preference displayed by the M 5 Ϫ/Ϫ mice is because of the lack of functional M 5 receptors and is not an artifact associated with a particular genetic background or mating scheme (33) .
Morphine-Stimulated Dopamine Release in the Acb. The activity of midbrain dopamine neurons projecting to the Acb has been implicated in the process of incentive salience and in mediating the conditioned rewarding effects of opiates (15) (16) (17) 34) . We (Fig. 2) . However, consistent with the reduced efficacy of morphine in producing conditioned rewarding effects, this response was ϩ/ϩ and M5 Ϫ/Ϫ mice do not differ in the development of acute tolerance to morphine analgesia. Tolerance was assessed by determining the analgesic potency of morphine (10 mg͞kg i.p.) 24 hr after administration of a single dose of morphine (100 mg͞kg i.p.). a, Significantly different from the corresponding naive groups, P Ͻ 0.01, n ϭ 9 -14. All experiments were carried out with 129SvEv͞CF1 hybrid mice. To exclude the possibility that the lack of M 5 receptors led to secondary changes in dopamine receptor densities, we also investigated the binding of D1 ([ 3 H]SCH23390, 4 nM) and D2 ([ 3 H]spiperone, 2 nM) receptor-selective radioligands in striatum and midbrain, the two brain regions in which M 5 receptors are preferentially expressed (9, 10) . We found that D1 and D2 dopamine receptor levels in these two brain regions were not significantly affected (P Ͼ 0.05, unpaired two-tailed Student's t test) by the absence of functional M 5 receptors (129SvEv͞CF1 hybrid mice). Specifically, the following receptor densities were obtained: fmol͞mg protein, Ϫ/Ϫ mice to the anti-nociceptive effects of morphine was evaluated using the tail-flick and hot-plate tests (22) . In M 5 ϩ/ϩ mice (129SvEv͞CF1 hybrids), morphine (2.5, 5, and 10 mg͞kg i.p.) produced dose-related analgesic effects in both assays (Fig.  3A) . The magnitude of these responses remained essentially unaltered in M 5 Ϫ/Ϫ mice (Fig. 3A) . Moreover, M 5 ϩ/ϩ and M 5 Ϫ/Ϫ mice developed a similar degree of tolerance to morphineinduced analgesia. This is illustrated in Figs. 3B and 4 , which show the development of morphine tolerance 24 h after administration of a single high dose of morphine (100 mg͞kg i.p.) or The long-term synaptic changes that develop after chronic morphine administration are associated with elevated expression levels of Fos-related immediate early gene products including Fos-B (29) . Consistent with this finding, immunoblot analysis showed that chronic administration of morphine (75 mg s.c. pellet, 7 days) led to a significant increase in Fos-B expression in the Acb of M 5 ϩ/ϩ mice (Fig. 5A, 129SvEv͞CF1 hybrids) . Strikingly, the magnitude of this response was greatly reduced in M 5 Ϫ/Ϫ mice (Fig. 5A ). In agreement with this observation, the morphine-induced increase in Fos-B expression observed in M 5 ϩ/ϩ mice was blocked by coadministration of the centrally active muscarinic antagonist, atropine (administered s.c. via osmotic minipumps at a dose of 15 mg͞kg per day for 7 days, Fig. 5B ).
Naloxone-Induced Withdrawal Symptoms and Conditioned Place
Aversion in Mice Chronically Treated with Morphine. Naloxone (1 mg͞kg i.p.) induced a characteristic spectrum of somatic withdrawal signs in M 5 ϩ/ϩ and M 5 Ϫ/Ϫ mice chronically treated with morphine (75 mg s.c. pellet, 7 days; Fig. 6 ). However, the severity of withdrawal symptoms was significantly reduced in M 5 Ϫ/Ϫ mice (Fig. 6 ). These differences were observed independent of whether M 5 Ϫ/Ϫ mice (129SvEv͞CF1 hybrids, 50%͞50%) were obtained by homozygous matings (age-matched mice) or by crosses of heterozygous M 5 ϩ/Ϫ mice (littermates) (Fig. 6 ). As observed with the M 5 Ϫ/Ϫ hybrid mice, isogenic M 5 Ϫ/Ϫ mice carrying the M 5 receptor mutation on a pure genetic background (129SvEv) showed similar reductions in the severity of morphine withdrawal symptoms (Fig. 6 ). These findings rule out the possibility that the observed differences in the severity of withdrawal symptoms were an artifact caused by a particular genetic background or mating scheme (33) .
In addition to the above somatic manifestations of naloxone- Finally, the conditioned aversive effects of morphine with- drawal were investigated using the CPP paradigm (23, 30) . In M 5 ϩ/ϩ mice (129SvEv mice) chronically treated with morphine (75 mg s.c. pellet, 7 days), the opioid antagonist, naloxone (1 mg͞kg i.p.), induced a pronounced conditioned place aversion response, as indicated by a significant reduction in the amount of time M 5 ϩ/ϩ mice spent in the naloxone-paired chamber (Fig.  7) . The magnitude of this effect was significantly reduced (by Ϸ50%) in M 5 Ϫ/Ϫ mice (Fig. 7) . In summary, we demonstrate that M 5 Ϫ/Ϫ mice displayed a significant reduction in morphine-induced CPP and the severity of the naloxone-precipitated withdrawal syndrome. These data are consistent with the concept that M 5 receptor activation stimulates midbrain dopaminergic neurons (7, (9) (10) (11) , thus modulating the behavioral manifestations of both morphine reward and withdrawal. Because at least some of the reinforcing properties of other drugs of abuse, including nicotine, alcohol, and cocaine, also involve mesocorticolimbic dopaminergic pathways (15) (16) (17) , it is possible that M 5 receptors have a more general role in modulating drug-seeking behavior. In agreement with this hypothesis, preliminary studies showed that cocaine-induced CPP was also significantly reduced in M 5 Ϫ/Ϫ mice (I.F., J.W., and A.S.B., unpublished results).
Yeomans et al. (36) recently showed that central administration of an M 5 receptor antisense oligonucleotide decreased the sensitivity to rewarding hypothalamic stimulation in rats, as assessed in a bar-pressing paradigm. These data further support the concept that M 5 receptors play a key role in modulating behavioral processes that are dependent on the activity of midbrain dopaminergic neurons.
Whereas the rewarding effects of morphine were substantially reduced in M 5 Ϫ/Ϫ mice, the analgesic efficacy of morphine remained unaffected by the lack of M 5 receptors. Morphine and other opiate analgesics are widely used for the control of severe pain, but they have a high potential of abuse and dependence (37) . Our data therefore suggest that disruption of M 5 receptor function, e.g., by administration of centrally active, selective M 5 receptor antagonists, may represent a strategy to reduce the abuse liability of opiates without affecting their analgesic properties. Because M 5 receptors show a relatively restricted localization in the brain (9, 10) and the lack of M 5 receptors does not lead to significant peripheral muscarinic side effects (7), it is likely that such agents will be well tolerated.
Our results underscore the usefulness of M 5 Ϫ/Ϫ mice as experimental tools for delineating the behavioral and pharmacological roles of the M 5 muscarinic receptor subtype.
